Seattle Genetics, Inc.

Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Bayer Aktiengesellschaft

Sven Golfier

Jörg Willuda

Joachim Schuhmacher

Hans-Georg Lerchen

Beatrix Stelte-Ludwig

Simon Holton

Christoph Freiberg

Uwe Gritzan

Frank Dittmer

Dorian Schönfeld

Julian Marius Glück

Jessica Pinkert

Eva-Maria Gutierrez

Philip Beckhove

Yingzi Ge

Ursula Krenz

Mark Trautwein

Gerhard Siemeister

Antje Margret Wengner

Karl-Heinz Thierauch

Mark Jean Gnoth

Sherif El Sheikh

Simone Greven

Christoph Mahlert

Iring Heisler

Charlotte Christine Kopitz

Lars Linden

Axel Harrenga

Sandra Bruder

Hannah Jöriβen

Jean Mark Gnoth

Li Liu

Sandra Borkowski

Bernard Händler

Andreas Schlicker

Rudolf Beier

Heike Petrul

Gutierrez Eva-Maria

The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called 'Compound A'), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject. Preferably the hyper-proliferative disease or the subject is characterized by one or more biomarker(s) selected from The present invention also covers a kit comprising Compound A together with means to detect one or more of the aforementioned biomarker(s) and a method for identifying a subject having a hyper-proliferative disease disposed to respond favorably to Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s). Further, the invention covers a method of determining whether a subject having a hyper-proliferative disease will respond to the treatment with Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s) in a sample of the subject.

Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human andCEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-CEACAM6 antibodies and uses thereof

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Binder-drug conjugates (ADCs) and use thereof

The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.

N-carboxyalkyl-auristatin and the use thereof

The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Auristatin derivatives and use thereof

Growing community of inventors

Berlin, Germany

Sven Golfier